通过多巴胺和相关分子调节α-synuclein形态组合和聚合途径
Antonino Natalello1, Stefania Brocca1, Erika Ponzini2,3
1Department of Biotechnology and Biosciences, University of Milano-Bicocca, 20126 Milan, Italy.
Frontiers in bioscience (Landmark edition)
|November 2, 2023
概括
了解α-synuclein (AS) 和多巴胺 (DA) 相互作用是开发帕金森病 (PD) 药物的关键. 本综述探讨了AS的结构变化,聚合,以及用于新型治疗策略的带结合.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 多巴胺能神经元面临来自α-synuclein (AS) 结构障碍和多巴胺 (DA) 代谢的威胁.
- 帕金森病 (PD) 的发病与病理性AS结构变化有关.
研究的目的:
- 审查AS形态转换,聚合途径和连接体结合的相互关联方面.
- 检查AS与DA的相互作用,其代谢产物,类似物和激动剂.
主要方法:
- 对AS研究近期进展的文献综述.
- 分析AS,其聚合物和连接物的结构性质.
- 讨论在AS研究中使用的方法.
主要成果:
- 确定了AS,其聚合物和连接物的突出结构特征.
- 突出了AS结构,聚合和DA相互作用之间的复杂关系.
- 强调正在进行的辩论和需要进一步调查的领域.
结论:
- 了解AS的结构动力学和连接体相互作用对于PD药物发现至关重要.
- 需要进一步的实验和计算研究来确定新的疾病修饰剂.
- 准AS-连接体相互作用可能为帕金森病提供新的治疗途径.
关键词:
类甲基胺 (Catecholamines) 是一种类甲基胺.本质上是无序的蛋白质.带结合的结合方式氧化应激是一种氧化应激.合成核蛋白病变 (synucleinopathies) 是一种同核蛋白病变.更多相关视频
08:40Millisecond Hydrogen/Deuterium-Exchange Mass Spectrometry for the Study of Alpha-Synuclein Structural Dynamics Under Physiological Conditions
Published on: June 23, 2022
3.0K
08:24A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model
Published on: November 25, 2022
2.2K
相关概念视频
Neural Regulation
39.5K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.5K
Amyloid Fibrils
9.6K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.6K
Parkinson's Disease: Overview
564
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
564
Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
Parkinson's Disease: Treatment
281
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
281
